Clinical Development

© GettyImages/Mohammed Haneefa Nizamudeen

Setback for Novartis drug in advanced lung cancer trial

By Jane Byrne

Novartis reported today that a clinical trial of the drug, known as canakinumab, when combined with chemotherapy agent, docetaxel, failed to extend the lives of patients with advanced or metastatic non-small cell lung cancer compared to just chemotherapy...

Follow us

Products

View more

Webinars